Navigation Links
Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
Date:2/11/2010

CAMBRIDGE, Mass., Feb. 11 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP; Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida. Data from a pediatric subgroup of this study and five year follow-up results from a long-term Phase I/II extension study (TKT025 EXT) conducted in adults were also reported and add to the available data on the long-term safety and efficacy of velaglucerase alfa in patients with Type 1 Gaucher disease.

Both studies (TKT032 and TKT025 EXT) met their primary end-points.

Additionally, Shire reported important findings from a study that compared patient antibody response to velaglucerase alfa and imiglucerase. All patients enrolled in the velaglucerase alfa Phase III clinical studies underwent a comprehensive panel of tests that were developed and validated to assess antibody response. In each study, samples were first screened using an electrochemiluminescence (ECL) assay. Positive samples were confirmed using a quantitative radioimmunoprecipitation (RIP) assay. Positive cut-points were established for the ECL assay as 5 ng/mL as well as in terms of fixed raw counts, and for the RIP assay as 4 ng/mL. The results suggest significant antigenic differences between velaglucerase alfa and imiglucerase, with only 1% seroconversion rates against velaglucerase alfa.

"The combined data presented today provides additional and compelling support f
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
2. Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter(TM) Page
3. Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
4. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
5. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
6. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
7. Shire Continues to Deliver Excellent Growth From Core Products
8. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
9. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
10. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
11. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets has announced the ... Strategic Business Report" report to their offering. ... Hormone Drugs in US$ Million by the following Brands: Humatrope, ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , and Rest of ...
(Date:8/19/2014)... -- Avizia, Inc., a leading provider of cutting-edge telemedicine ... financing round led by NextGen Angels along with Blu ... be used to continue to fuel the rapidly growing ... Edward Kennedy , CEO and president of Tollgrade Communications, ... Kurtzman , CFO of newBrandAnalytics, who joined the board ...
(Date:8/19/2014)... 19, 2014  SCILEX Pharmaceuticals, Inc., a company engaged ... for the treatment of pain, announced that it had formed ... Jeff Gudin , Dr. Charles Argoff , ... Vought . SCILEX Chief Executive Officer ... board would greatly assist in the development and commercialization ...
Breaking Medicine Technology:Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Avizia Closes Funding Round 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4
(Date:8/20/2014)... In a recent article published by the ... (UCL) study showed that dental experts from around the ... was the most effective. Analysis of 66 different advice ... frequently recommended, but none were favored by a majority. ... experienced cosmetic dentist Dr. Patrick J. Broome, DMD, ...
(Date:8/20/2014)... 20, 2014 Biosimilars, which are ... approved through an abbreviated process, could reap billions ... Atlantic Information Services, Inc.’s (AIS) Specialty Pharmacy News ... including the Food and Drug Administration’s (FDA) recent ... towards approval. , Drugmaker Sandoz said July 24 ...
(Date:8/20/2014)... August 20, 2014 “Have you recently been ... accident and personal injury lawyer serving the greater Seattle area. ... If so, then keep reading . , In a ... injured in an auto accident can use to see if ... that a personal injury insurance claim will allow an individual ...
(Date:8/20/2014)... August 20, 2014 Low market concentration, ... availability of substitutes typify the market for packaging design ... 3.1 out of 5, indicating a moderate level of ... and suppliers have an equal amount of leverage during ... , First, few substitutes exist for packaging design ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 First ... freestanding emergency rooms in the United States, named Richard ... – FM 685 facility. , “We are pleased ... medical director of our second facility in Pflugerville,” said ... Choice Emergency Room. , Dr. Daniels received his ...
Breaking Medicine News(10 mins):Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2
... , , MIAMI, ... toys manufactured in China sent parents searching frantically for gifts ... refunds suggested that even so-called educational toys are suspect. Renowned ... are actually harmful to developing brains, retarding language development and ...
... , LONDON, Dec. 7 The National Health ... people in the UK, understands the value of an engaged ... initiative to improve the value of care, many NHS hospitals ... Tanner Company, to train hospital leaders. , "Staff engagement is ...
... , , BOCA RATON, ... the market leader in all-natural herbal and homeopathic remedies for ... as their PR firm of record. The company,s two brands, ... provide complete lines of safe, scientifically-tested, guaranteed products that promote ...
... ... has begun his work as the new worldwide executive director of the Drug Information ... ... MBA, CAE, officially has begun his work as the new worldwide executive director of ...
... , PARSIPPANY, N.J., Dec. 7 Today the Centers for ... Vaccination Week. While the week was designed to highlight the importance ... taking additional steps to keep you and your family healthy during ... , "It,s easy to get overwhelmed by all the information circulating ...
... may be able to reverse some of the damage to ... their cigarettes, according to research out of the University of ... in the December 15 issue of the American Thoracic Society,s ... "We found that exposure to cigarette smoke appears to ...
Cached Medicine News:Health News:Top 10 Toys That Will Scar Your Child for Life 2Health News:The NHS to Improve Patient Care by Better Engaging Staff 2Health News:Native Remedies and PetAlive.com Hires TransMedia Group to Herald Herbal for People and Pets 2Health News:New DIA Vision And Mission Coincides With Start of Paul Pomerantz Tenure As Worldwide Executive Director 2Health News:New DIA Vision And Mission Coincides With Start of Paul Pomerantz Tenure As Worldwide Executive Director 3Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 2Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 3Health News:Quitting smoking can reverse asthma-inducing changes in lungs 2
For the quantitative determination of Albumin in serum. Endpoint procedure with Amax at 630 nm. Linearity: to 6 g/dl. Liquid ready-to-use reagent....
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
AST (SGOT) reagent is used for the quantitative determination of aspartate aminotransferase (AST) in human serum....
For the quantitative colorimetric determination of AST (SGOT) in serum....
Medicine Products: